Fluid biomarker pT217Tau demonstrates that soluble tau pathology begins early in disease progression.

Clinical Score: 0.500 Price: $0.50 Alzheimer's disease human Status: extracted

What This Experiment Tests

Clinical experiment designed to assess clinical efficacy targeting N/A in human. Primary outcome: Fluid biomarker pT217Tau demonstrates that soluble tau pathology begins early in disease progression

Description

Fluid biomarker detection of phosphorylated tau (pT217Tau)

TARGET GENE

N/A

MODEL SYSTEM

human

ESTIMATED COST

TIMELINE

0 months

PATHWAY

tau pathology

SOURCE

pmid_40767321

PRIMARY OUTCOME

Fluid biomarker pT217Tau demonstrates that soluble tau pathology begins early in disease progression.

Scoring Dimensions

Related Hypotheses (1)

TREM2 Antagonism in Late-Stage Tauopathy — Reducing Neuroinflammatory Amplification0.628

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.